Pacific Biosciences of California (PACB)

Official site

HEALTHCARE • MEDICAL DEVICES • NASDAQ

$1.99

-0.06 (-2.93%)

Market Cap: $618.55M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

67%(26/39)

Avg Surprise

-1.19%

Streak

6 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.13

Range$-0.14 - $-0.12

7 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.13-3.1%

60d ago$-0.13-3.6%

30d ago$-0.13-1.0%

7d ago$-0.13-1.9%

Current$-0.13

Revenue Consensus

$39M

Range$37M - $42M

6 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.13

Range$-0.14 - $-0.11

7 analysts

Revenue Consensus

$39M

Range$33M - $42M

6 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.13	$-0.14 - $-0.11	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.13	$-0.14 - $-0.12	-	-	7	1 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 3, 2026Reported Aug 3	$-0.14	$-0.14	$-0.14 - $-0.12	+0.00%	Beat	5	2 1 30d	-7.7%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.12	$-0.13	$-0.17 - $-0.11	+7.69%	Beat	7	0 1 30d	+20.0%
Dec 31, 2025Dec 25 Reported Feb 12, 2026Reported Feb 12	$-0.12	$-0.13	$-0.15 - $-0.12	+7.69%	Beat	8	0 1 30d	+40.0%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.12	$-0.16	$-0.16 - $-0.12	+25.00%	Beat	7	6 0 30d	+29.4%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-0.13	$-0.18	$-0.18 - $-0.14	+27.78%	Beat	9	2 0 30d	+35.0%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-0.15	$-0.19	$-0.20 - $-0.17	+21.05%	Beat	10	1 2 30d	+42.3%
Dec 31, 2024Dec 24 Reported Feb 13, 2025Reported Feb 13	$-0.20	$-0.17	$-0.21 - $-0.11	-17.65%	Miss	10	1 1 30d	+25.9%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-0.17	$-0.21	$-0.30 - $-0.16	+19.05%	Beat	12	1 0 30d	+37.0%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.20	$-0.22	$-0.29 - $-0.19	+9.09%	Beat	13	No revisions (30d)	+23.1%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.26	$-0.26	$-0.32 - $-0.23	+0.00%	Beat	13	4 0 30d	+16.1%
Dec 31, 2023Dec 23 Reported Feb 15, 2024Reported Feb 15	$-0.27	$-0.28	$-0.35 - $-0.24	+3.57%	Beat	15	2 1 30d	+27.0%
Sep 30, 2023Sep 23 Reported Oct 30, 2023Reported Oct 30	$-0.27	$-0.29	$-0.66 - $-0.26	+6.90%	Beat	10	2 0 30d	+15.6%
Jun 30, 2023Jun 23 Reported Aug 2, 2023Reported Aug 2	$-0.26	$-0.31	$-0.36 - $-0.29	+16.13%	Beat	11	No revisions (30d)	+23.5%
Mar 31, 2023Mar 23 Reported May 2, 2023Reported May 2	$-0.31	$-0.33	$-0.39 - $-0.29	+6.06%	Beat	8	No revisions (30d)	+16.2%
Dec 31, 2022Dec 22 Reported Feb 16, 2023Reported Feb 16	$-0.37	$-0.36	$-0.40 - $-0.34	-2.78%	Miss	8	No revisions (30d)	-23.3%
Sep 30, 2022Sep 22 Reported Nov 7, 2022Reported Nov 7	$-0.32	$-0.33	$-0.36 - $-0.31	+3.03%	Beat	6	No revisions (30d)	-39.1%
Jun 30, 2022Jun 22 Reported Aug 3, 2022Reported Aug 3	$-0.34	$-0.34	$-0.37 - $-0.24	+0.00%	Beat	6	2 0 30d	-61.9%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-0.37	$-0.32	$-0.33 - $-0.22	-15.63%	Miss	6	No revisions (30d)	+17.8%
Dec 31, 2021Dec 21 Reported Feb 15, 2022Reported Feb 15	$-0.30	$-0.29	$-0.29 - $-0.28	-3.45%	Miss	6	1 0 30d	-150.0%
Sep 30, 2021Sep 21 Reported Nov 2, 2021Reported Nov 2	$-0.23	$-0.24	$-0.24 - $-0.21	+4.17%	Beat	4	No revisions (30d)	-64.3%
Jun 30, 2021Jun 21 Reported Aug 3, 2021Reported Aug 3	$-0.21	$-0.21	$-0.22 - $-0.18	+0.00%	Beat	5	1 0 30d	-40.0%
Mar 31, 2021Mar 21 Reported Apr 29, 2021Reported Apr 29	$-0.45	$-0.31	$-0.34 - $-0.26	-45.16%	Miss	5	No revisions (30d)	-114.3%
Dec 31, 2020Dec 20 Reported Feb 10, 2021Reported Feb 10	$-0.12	$-0.12	-	+0.00%	Beat	5	1 0 30d	-9.1%
Sep 30, 2020Sep 20 Reported Nov 2, 2020Reported Nov 2	$-0.14	$-0.13	$-0.15 - $-0.13	-7.69%	Miss	5	1 0 30d	+17.6%
Jun 30, 2020Jun 20 Reported Aug 3, 2020Reported Aug 3	$-0.15	$-0.18	$-0.23 - $-0.14	+16.67%	Beat	3	No revisions (30d)	-7.1%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$-0.21	$-0.15	$-0.18 - $-0.14	-40.00%	Miss	4	No revisions (30d)	-31.2%
Dec 31, 2019Dec 19 Reported Feb 6, 2020Reported Feb 6	$-0.11	$-0.14	$-0.18 - $-0.14	+21.43%	Beat	3	No revisions (30d)	+47.6%
Sep 30, 2019Sep 19 Reported Nov 7, 2019Reported Nov 7	$-0.17	$-0.15	$-0.17 - $-0.13	-13.33%	Miss	4	No revisions (30d)	+10.5%
Jun 30, 2019Jun 19 Reported Aug 6, 2019Reported Aug 6	$-0.14	$-0.14	$-0.19 - $-0.12	+0.00%	Beat	4	No revisions (30d)	+17.6%
Mar 31, 2019Mar 19 Reported May 3, 2019Reported May 3	$-0.16	$-0.16	$-0.20 - $-0.13	+0.00%	Beat	5	No revisions (30d)	+20.0%
Dec 31, 2018Dec 18 Reported Feb 11, 2019Reported Feb 11	$-0.21	$-0.13	$-0.15 - $-0.12	-61.54%	Miss	5	No revisions (30d)	-16.7%
Sep 30, 2018Sep 18 Reported Nov 1, 2018Reported Nov 1	$-0.19	$-0.15	$-0.17 - $-0.13	-26.67%	Miss	7	No revisions (30d)	+0.0%
Jun 30, 2018Jun 18 Reported Aug 2, 2018Reported Aug 2	$-0.17	$-0.17	$-0.18 - $-0.15	+0.00%	Beat	5	No revisions (30d)	+34.6%
Mar 31, 2018Mar 18 Reported May 2, 2018Reported May 2	$-0.20	$-0.19	$-0.20 - $-0.18	-5.26%	Miss	6	No revisions (30d)	+23.1%
Dec 31, 2017Dec 17 Reported Feb 1, 2018Reported Feb 1	$-0.18	$-0.20	$-0.21 - $-0.18	+10.00%	Beat	6	No revisions (30d)	+14.3%
Sep 30, 2017Sep 17 Reported Nov 2, 2017Reported Nov 2	$-0.19	$-0.19	$-0.23 - $-0.18	+0.00%	Beat	6	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Aug 2, 2017Reported Aug 2	$-0.26	$-0.24	$-0.26 - $-0.22	-8.33%	Miss	6	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported Apr 26, 2017Reported Apr 26	$-0.26	$-0.23	-	-13.04%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Feb 2, 2017Reported Feb 2	$-0.21	$-0.23	-	+8.70%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-3.98	EV/EBITDA	N/A
Price/FCF	-5.00x	FCF Yield	-19.99%
Profitability
Profit Margin	-82.50%	Operating Margin	-114.40%
ROE	-929.00%	ROIC	-20.16%
Financial Health
Debt/Equity	-19.40x	Interest Coverage	-16.81x
Current Ratio	4.92x	Quick Ratio	4.03x
Trading Statistics
Beta	2.19	Avg Volume	18.59M
52-Week High	$3.44	52-Week Low	$1.07

Technical Indicators Dashboard

Moving Averages

SMA 10$2.41

SMA 20$2.01

SMA 50$1.58

SMA 200$1.59

EMA 10$2.20

EMA 20$2.05

EMA 50$1.76

EMA 200$1.58

MACD

Line: 0.21Signal: 0.25Hist: -0.04

ADX

ADX: 46.7+DI: 32.9-DI: 14.9

Aroon & PSAR

Aroon Up76.0

Aroon Down4.0

PSAR$3.18

Bollinger Bands

Upper Band$3.03

Lower Band$0.99

%B Position10121%(Upper)

Band Width0.49

RSI (14-Day)

Neutral

51.2

Momentum Oscillators

Stoch %K30.7

Stoch %D37.2

Williams %R-75.5

ROC (10d)-16.0%

Momentum-0.38

CCI (20d)0.8

MFI (14d)74.7

Volatility Measures

ATR (14d)$0.24(12.3%)

StdDev (20d)0.51

Hist Vol149.0%(High)

Volume Flow

VWAP$2.00

OBV101.5M

AD Line-28.7M

CMF (20d)0.262

Volume Metrics

Avg Vol (20d)19.9M

Vol Ratio0.5x(Low)

VWMA (20d)$2.27

Pivot Points

R3$2.27

R2$2.21

R1$2.13

Pivot Point$2.06

S1$1.98

S2$1.91

S3$1.83

Advanced Oscillators

TSI27.79

Ultimate Osc42.6

KST742.53

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$39.01M	$37.18M	$44.65M	$38.44M	$39.77M	$37.15M	$39.22M	$39.97M	$36.01M	$38.81M	$58.36M	$55.69M
Cost of Revenue	$26.37M	$24.34M	$28.08M	$22.54M	$25.08M	$38.52M	$29.17M	$29.96M	$30.07M	$27.53M	$48.79M	$37.79M
Gross Profit	$12.64M	$12.84M	$16.57M	$15.90M	$14.68M	$-1,371,000	$10.06M	$10.00M	$5.94M	$11.28M	$9.57M	$17.90M

Operating Expenses	$57.25M	$21.20M	$57.76M	$54.78M	$59.54M	$427.56M	$163.09M	$74.08M	$181.78M	$92.64M	$97.12M	$100.39M
R&D	$23.02M	$19.61M	$22.88M	$22.85M	$22.53M	$29.05M	$27.47M	$25.52M	$38.48M	$43.45M	$44.54M	$47.51M
SG&A	$33.39M	$31.15M	$34.05M	$31.10M	$36.17M	$40.17M	$41.64M	$43.75M	$45.88M	$43.75M	$46.00M	$43.43M
Operating Income	$-44,610,000	$-8,357,000	$-41,197,000	$-38,877,000	$-44,853,000	$-428,934,000	$-153,028,000	$-64,077,000	$-175,846,000	$-81,362,000	$-87,548,000	$-82,492,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$2.11M	$1.74M	$1.74M	$1.74M	$1.74M	$1.74M	$-151,650,000	$3.54M	$3.54M	$3.58M	$3.57M	$3.59M
Income Before Tax	$-44,683,000	$-8,091,000	$-40,169,000	$-37,617,000	$-41,895,000	$-426,377,000	$2.69M	$-60,725,000	$-173,319,000	$-78,178,000	$-82,736,000	$-77,575,000
Income Tax Expense	$58,000	$184,000	$202,000	$383,000	$35,000	$-302,000	$316,000	$0	$0	$0	$-718,000	$-10,706,000

Net Income	$-44,741,000	$-8,275,000	$-40,371,000	$-38,000,000	$-41,930,000	$-426,075,000	$2.37M	$-60,725,000	$-173,319,000	$-78,178,000	$-82,018,000	$-66,869,000

EBITDA	$-37,757,000	$-2,577,000	$-34,240,000	$-32,399,000	$-33,869,000	$-53,567,000	$-140,395,000	$-44,179,000	$-159,029,000	$-66,620,000	$-70,218,000	$-72,507,000
EBIT	$-42,573,000	$-6,351,000	$-38,429,000	$-35,878,000	$-40,157,000	$-424,640,000	$-148,963,000	$-57,187,000	$-169,777,000	$-74,603,000	$-79,165,000	$-73,987,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about PACB

Government Contracts

Gov Obligations (TTM)

$2.22M

Gov Obligations / Revenue

1.4%

Obligations YoY

21.0%

Active Awards

New Awards (TTM)

Avg Remaining Term

10.9 mo

Top agency: Department of Agriculture at 51.8% of trailing twelve month obligations across 3 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
75N98026P00928	Department of Health and Human ServicesNational Institutes of Health	$346907	Jul 8, 2026	Jul 7, 2027	NHGRI: SUPPLY: SEQUENCING REAGENTS: N/A
1232SA26F0221	Department of AgricultureAgricultural Research Service	$240216	Apr 29, 2026	Sep 30, 2026	LONG-READ SEQUENCING REAGENTS OF WHOLE GENOME ANALYSES
1232SA25F0277	Department of AgricultureAgricultural Research Service	$232854	Sep 24, 2025	Sep 30, 2026	PACBIO REAGENT KITS. ALL REAGENTS FOR SEQUENCING 24 REVIO SMRT CELLS QUANTITY 8, AND ASSOCIATED LIBRARY PREP REAGENTS.
75N92025P00381	Department of Health and Human ServicesNational Institutes of Health	$198083	Sep 16, 2025	Sep 26, 2026	REVIO SMRT CELLS AND SEQUENCING REAGENTS - NEW AWARD
1232SA25F0455	Department of AgricultureAgricultural Research Service	$194861	Sep 22, 2025	Jun 30, 2026	REVIO SPRQ REAGENT KIT, 24-PACK, PACIFIC BIOSCIENCES OF CALIFORNIA (NON-IT)
1232SA25F0317	Department of AgricultureAgricultural Research Service	$171500	Sep 3, 2025	Oct 3, 2025	VEGA BENCHTOP LONG READ SEQUENCER FROM PACIFIC BIOSCIENCES A LONG READ GENOMIC SEQUENCER THAT PROVIDES HIGH ACCURACY READS VIA SINGLE MOLECULE REAL TIME SEQUENCING THAT ARE 10-20KB IN LENGTH. BASE CALLING, DEMULTIPLEXING, AND FILE FORMATION ALL DO
75N98026P00331	Department of Health and Human ServicesNational Institutes of Health	$85000	Jul 25, 2026	Jul 24, 2027	THE NISC LABORATORY SUPPLIES STATE OF THE ART SEQUENCING SERVICES TO INSTITUTES THROUGHOUT THE NIH. THE HIGHLY ACCURATE LONG-READ SEQUENCE DATA PRODUCED BY THE PACBIO REVIO IS CRITICAL FOR CERTAIN TYPES OF EXPERIMENTS. THIS EQUIPMENT IS THEREFORE A V
1232SA26F0132	Department of AgricultureAgricultural Research Service	$85000	Jul 12, 2026	Jul 11, 2027	REVIO SERVICE CONTRACT - PRODUCT CODE 102-873-100 - SERIAL NUMBER 84124
75N92025P00290	Department of Health and Human ServicesNational Institutes of Health	$85000	Aug 1, 2025	Jul 31, 2026	SERVICE CONTRACT FOR PACIFIC BIOSCIENCES REVIO, NEW PO
1232SA26F0022	Department of AgricultureAgricultural Research Service	$83487	Dec 11, 2025	Dec 10, 2026	SERVICE CONTRACT FOR PACBIO REVIO

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

Six brokerages set USD 1.71 target for Pacific Biosciences stock

Six brokerages have set a consensus price target of USD 1.71 for Pacific Biosciences (PACB) stock, with an average rating of "Reduce." This target is 13.64 percent below the latest Nasdaq quote of USD 1.98. The company...

ad-hoc-news.de•Oct 15, 2026 5:18 PM ET10/15/26•Somewhat-Bearish

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors

Pacific Biosciences of California (PACB) closed down 2.93% in its latest trading session, underperforming the S&P 500, Dow, and Nasdaq. Despite this...

Yahoo! Finance Canada•Oct 14, 2026 5:40 PM ET10/14/26•Somewhat-Bearish

PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026

PacBio (NASDAQ: PACB) announced it will hold its quarterly conference call to discuss its third-quarter 2026 financial results on Wednesday, November 4, 2026...

GlobeNewswire•Oct 14, 2026 3:42 PM ET10/14/26•Neutral

PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics

PacBio has announced a collaboration with TychoBio to generate full-length RNA sequencing data for training AI models focused on developing RNA therapies for rare diseases. The partnership will initially concentrate...

TradingView•Oct 13, 2026 11:39 AM ET10/13/26•Somewhat-Bullish

PACB5949325 Bond Profile: Coupon and Redemption

This article provides a detailed profile of the PACB5949325 bond issued by Pacific Biosciences of California, Inc. It outlines key facts such as the issuer, issue and maturity dates, face value...

TradingView•Oct 13, 2026 5:39 AM ET10/13/26•Neutral

PACB Valuation and Fair Value

P/E: -4.0x
P/FCF: -5.0x
PEG: -0.2x
P/B: -18.6x

See GNG's fair value

PACB Profitability: Margins, ROIC and FCF

Gross margin: 36.4%
Operating margin: -114.4%
Net margin: -82.5%
ROIC: -20.2%
ROE: -929.0%
FCF margin: -77.6%
FCF yield: -20.0%

PACB Competitors

Company	Ticker
Performant Healthcare, Inc	PHLT
SurModics Inc	SRDX
Avalo Therapeutics Inc	AVTX
Zevra Therapeutics Inc.	ZVRA
Phreesia Inc	PHR
ProKidney Corp.	PROK
OmniAb Inc.	OABI
Sophia Genetics SA	SOPH

Sector: Healthcare

PACB Analyst Ratings

Consensus: Hold
Analysts: 8
Strong Buy: 0
Buy: 4
Hold: 3
Sell: 0
Strong Sell: 1

PACB Bull Case vs Bear Case

Bull case

PACB beat EPS estimates in 75.0% of its last 8 reported quarters.

Bear case

PACB has a -82.5% net profit margin.
PACB's quarterly revenue changed -1.9% year over year.

PACB Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: 11.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.13
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 3 down

Frequently Asked Questions About PACB

Does PACB pay dividends?

Pacific Biosciences of California (PACB) does not currently pay a regular dividend.

What is PACB's market cap?

Pacific Biosciences of California (PACB) has a market capitalization of $618.55M with a current stock price of $1.99.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In